Recursion Pharmaceuticals (RXRX) PT Raised to $5.50 at Morgan Stanley
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Price: $3.31 +2.48%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 15
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst Sean Laaman raised the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $5.50 (from $5.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Lake Street Downgrades Identiv, Inc. (INVE) to Hold
- Instacart (CART) PT Raised to $60 at Oppenheimer
- Micron Technology (MU) PT Raised to $2,000 at DA Davidson: Has 'Best Visibility'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
